Abstract:Inflammatory bowel disease (IBD) has become a serious and challenging health problem globally without curative medical treatments. Mounting evidence suggests that intestinal macrophages and their phenotypes are key players in the pathogenesis of IBD. Modulating the phenotypes and functions of intestinal macrophages through targeted interventions could be a promising approach to manage detrimental gut inflammation in IBD. In this study, we rationally design and fabricate a novel class of V-type peptide-decorated nanoparticles, VP-NP, with potent anti-inflammatory activity. Such a design allows two functional motifs FFD in a single peptide molecule to enhance the bioactivity of the nanoparticles. As expected, VP-NP exhibits a strong inhibitory activity on endosomal Toll-like receptor (TLR) signaling. Surprisingly, VP-NP can inhibit M1 polarization while facilitating M2 polarization in mouse bone marrow-derived macrophages through regulating the key transcription factors NF-κB, STAT1 and PPAR-γ. Mechanistically, VP-NP is internalized by macrophages in the endosomes, where it blocks endosomal acidification to inhibit endosomal TLR signaling; the transcriptomic analysis reveals that VP-NP potently down-regulates many genes in TLR, NF-κB, JAK-STAT, and cytokine/chemokine signaling pathways associated with inflammatory responses. In a colitis mouse model, the intraperitoneally administered VP-NP effectively alleviates the disease activities by decreasing colon inflammation and injuries, pro-inflammatory cytokine production, and myeloid cell infiltration in the gut. Furthermore, VP-NP primarily targets intestinal macrophages and alters their phenotypes from inflammatory M1-type toward the anti-inflammatory M2-type. This study provides a new nanotherapeutic strategy to specifically regulate macrophage activation and phenotypes through a dual mechanism to control gut inflammation, which may augment current clinical treatments for IBD.

Targeting Nrf2 by bioactive peptides alleviate inflammation: expanding the role of gut microbiota and metabolites.

The Alteration of Gut Microbiota by Bioactive Peptides: a Review

Nrf2 Signaling Pathway: Pivotal Roles in Inflammation.

Targeting NF-B pathway by dietary lignans in inflammation: expanding roles of gut microbiota and metabolites

Targeting NF-κB pathway by dietary lignans in inflammation: expanding roles of gut microbiota and metabolites

The Potential of Food Protein-Derived Bioactive Peptides against Chronic Intestinal Inflammation

Therapeutic peptides in the treatment of digestive inflammation: Current advances and future prospects

Advances in the application and mechanism of bioactive peptides in the treatment of inflammation

An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation

Regulation of Immunomodulatory Networks by Nrf2-activation in Immune Cells: Redox Control and Therapeutic Potential in Inflammatory Diseases

Do Short Chain Fatty Acids and Phenolic Metabolites of the Gut Have Synergistic Anti-Inflammatory Effects? - New Insights from a TNF-α-induced Caco-2 Cell Model.

Anti-Inflammatory Function of Plant-Derived Bioactive Peptides: A Review

A major mechanism for immunomodulation: Dietary fibres and acid metabolites

Targeted V-type peptide-decorated nanoparticles prevent colitis by inhibiting endosomal TLR signaling and modulating intestinal macrophage polarization

Food-derived peptides as novel therapeutic strategies for NLRP3 inflammasome-related diseases: a systematic review

Bioactive dietary peptides and amino acids in inflammatory bowel disease

An insight into role of amino acids as antioxidants via NRF2 activation

The role of quercetin in NLRP3-associated inflammation

Guidelines for Assessing the Capacity of Food‐derived Nutrients to Alleviate Intestinal Inflammation

The Efficacy of Anti-Proteolytic Peptide R7I in Intestinal Inflammation, Function, Microbiota, and Metabolites by Multi-Omics Analysis in Murine Bacterial Enteritis

Molecular Targets and Mechanisms of Bioactive Peptides Against Metabolic Syndromes